胆固醇7α-基酶 (CYP7A1) 的药理学调节作为高胆固醇血清症的治疗策略
Megan Yu Cai Lim1, Han Kiat Ho1
1Department of Pharmacy, Faculty of Science, National University of Singapore, 18 Science Drive 4, Singapore 117543, Singapore.
Biochemical pharmacology
|December 28, 2023
概括
针对胆固醇7α-基酶 (CYP7A1) 的新疗法为管理高胆固醇血症提供了新的途径. 用CYP7A1表达调节器调节法尔内索伊德X受体 (FXR) 途径可能提供有效的降胆固醇选择.
科学领域:
- 生物化学 生物化学
- 药理学 药理学是指药理学的学科.
- 代谢疾病 代谢疾病
背景情况:
- 高胆固醇血症仍然是一个普遍的健康问题,尽管现有的治疗方法.
- 需要新的治疗策略来有效地管理高胆固醇水平并减少不良影响.
- 胆固醇7α-基酶 (CYP7A1) 在胆固醇代谢和胆酸合成中起着至关重要的作用.
研究的目的:
- 审查CYP7A1在胆固醇平衡中的作用.
- 探索通过Farnesoid X受体 (FXR) 依赖的途径对CYP7A1表达的调节.
- 将CYP7A1表达调节剂定位为高胆固醇血症的潜在治疗剂.
主要方法:
- 关于CYP7A1功能和调节的综合文献综述.
- 分析依赖FXR的通路,包括FXR/SHP和FXR/FGF19/FGFR4.
- 检查当前的高胆固醇血治疗方法和新兴的药理学药剂.
主要成果:
- 可以调节CYP7A1的表达,以控制胆酸合成和胆固醇代谢.
- FGFR4抑制剂和FXR抗体被确定为针对CYP7A1.1.的独特药理学药剂.
- 描述了FXR调解剂的机制和临床考虑因素.
结论:
- 通过FXR通路调节CYP7A1的表达,为高胆固醇血症提供了一个有前途的策略.
- FGFR4抑制剂和FXR对抗剂提供了新的治疗选择.
- 这些药物可以补充现有的治疗方法,如他类药物,以改善胆固醇管理.
相关概念视频
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
665
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
665
01:29Cholesterol: Significance and Regulation
551
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
551
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.8K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.8K
01:07Physiological Pharmacokinetic Models: Incorporating Hepatic Transporter-Mediated Clearance
40
Drug transporters are critical in drug absorption, distribution, and excretion processes. They should be included in physiological-based pharmacokinetic (PBPK) models, which help predict human drug disposition. However, predicting this is challenging during drug development, especially when liver transport is involved. However, with a realistic representation of body transport processes, an accurate model may be possible.
A recent model describes pravastatin's hepatobiliary excretion,...
A recent model describes pravastatin's hepatobiliary excretion,...
40
01:24Principles of Drug Action
6.0K
Drugs are chemical substances that modify biological responses by interacting with macromolecular targets such as receptors, ion channels, transporters, and enzymes. Pharmacodynamics describes the course of action of drugs leading to the physiological effect at a specific site in the body.
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
Drugs can be agonists or antagonists. Like the endogenous ligands, agonists always bind and activate the target to produce a cellular response. Agonist binding induces a conformational change which in turn...
6.0K
01:19Regulation of Metabolism
9.4K
Cellular needs and conditions vary from cell to cell and change within individual cells over time. For example, the required enzymes and energetic demands of stomach cells are different from those of fat storage cells, skin cells, blood cells, and nerve cells. Furthermore, a digestive cell works much harder to process and break down nutrients during the time that closely follows a meal compared with many hours after a meal. As these cellular demands and conditions vary, so do the amounts and...
9.4K